You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameHaloprogin
Accession NumberDB00793  (APRD01011)
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionHaloprogin is used as a topical ointment or cream in the treatment of Tinea infections. Tinea infections are superficial fungal infections caused by three species of fungi collectively known as dermatophytes (Trichophyton, Microsporum and Epidermophyton). Commonly these infections are named for the body part affected, including tinea corporis (general skin), tinea cruris (groin), and tinea pedis (feet). Haloprogin is a halogenated phenolic ether administered topically for dermotaphytic infections. The mechanism of action is unknown, but it is thought to be via inhibition of oxygen uptake and disruption of yeast membrane structure and function. Haloprogin is no longer available in the United States and has been discontinued.
Structure
Thumb
Synonyms
Haloprogin
Haloprogina
Haloprogine
Haloproginum
Halotex
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AloprogenWestwood
HalotexWestwood
MycandenSchering
MycilanSchering-Plough
PolikMeiji
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIAIU7053OWL
CAS number777-11-7
WeightAverage: 361.391
Monoisotopic: 359.837241291
Chemical FormulaC9H4Cl3IO
InChI KeyInChIKey=CTETYYAZBPJBHE-UHFFFAOYSA-N
InChI
InChI=1S/C9H4Cl3IO/c10-6-4-8(12)9(5-7(6)11)14-3-1-2-13/h4-5H,3H2
IUPAC Name
1,2,4-trichloro-5-[(3-iodoprop-2-yn-1-yl)oxy]benzene
SMILES
ClC1=CC(Cl)=C(Cl)C=C1OCC#CI
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenol ethers
Direct ParentPhenol ethers
Alternative Parents
Substituents
  • Phenol ether
  • Halobenzene
  • Chlorobenzene
  • Alkyl aryl ether
  • Aryl halide
  • Aryl chloride
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organoiodide
  • Organochloride
  • Organohalogen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed to treat fungal (Tinea) skin infections such as athlete's foot, jock itch, ringworm, and tinea versicolor.
PharmacodynamicsUsed as a topical ointment or cream in the treatment of Tinea infections. Tinea infections are superficial fungal infections caused by three species of fungi collectively known as dermatophytes (Trichophyton, Microsporum and Epidermophyton). Commonly these infections are named for the body part affected, including tinea corporis (general skin), tinea cruris (groin), and tinea pedis (feet).
Mechanism of actionHaloprogin is a halogenated phenolic ether administered topically for dermotaphytic infections. The mechanism of action is unknown, but is thought to be via inhibition of oxygen uptake and disruption of yeast membrane structure and function. There is a higher incidence of cutaneous side effects with haloprogin, including irritation, burning, vesiculation (blisters), scaling, and itching. It is generally used when the infection is unresponsive to other antifungals.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Dermatophytic fungi including Trichophyton, Microsporum and Epidermophyton
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.971
Blood Brain Barrier+0.9801
Caco-2 permeable+0.7613
P-glycoprotein substrateNon-substrate0.8197
P-glycoprotein inhibitor INon-inhibitor0.8892
P-glycoprotein inhibitor IINon-inhibitor0.9614
Renal organic cation transporterNon-inhibitor0.8024
CYP450 2C9 substrateNon-substrate0.8017
CYP450 2D6 substrateNon-substrate0.817
CYP450 3A4 substrateNon-substrate0.6163
CYP450 1A2 substrateInhibitor0.9082
CYP450 2C9 inhibitorNon-inhibitor0.6083
CYP450 2D6 inhibitorNon-inhibitor0.9101
CYP450 2C19 inhibitorInhibitor0.6549
CYP450 3A4 inhibitorNon-inhibitor0.8235
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7712
Ames testNon AMES toxic0.6364
CarcinogenicityNon-carcinogens0.731
BiodegradationNot ready biodegradable0.9606
Rat acute toxicity1.8412 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7112
hERG inhibition (predictor II)Non-inhibitor0.9133
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Westwood squibb pharmaceuticals inc
Packagers
  • Norega Laboratories Inc.
Dosage formsNot Available
Prices
Unit descriptionCostUnit
Halotin 1% cream1.53USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point114-115U.S. Patent 3,322,813.
logP5.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00601 mg/mLALOGPS
logP4.69ALOGPS
logP4.85ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)-5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area9.23 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity66.88 m3·mol-1ChemAxon
Polarizability26.82 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

U.S. Patent 3,322,813.

General References
  1. Harrison EF, Zwadyk P Jr, Bequette RJ, Hamlow EE, Tavormina PA, Zygmunt WA: Haloprogin: a topical antifungal agent. Appl Microbiol. 1970 May;19(5):746-50. [PubMed:5422306 ]
  2. Harrison EF, Zygmunt WA: Haloprogin: mode of action studies in Candida albicans. Can J Microbiol. 1974 Sep;20(9):1241-5. [PubMed:4608935 ]
External Links
ATC CodesD01AE11
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (43.8 KB)
Interactions
Drug Interactions
Drug
AmlodipineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Amlodipine.
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Haloprogin.
AmrinoneThe risk or severity of adverse effects can be increased when Haloprogin is combined with Amrinone.
AzelnidipineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Azelnidipine.
AzimilideThe risk or severity of adverse effects can be increased when Haloprogin is combined with Azimilide.
BarnidipineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Barnidipine.
BenidipineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Benidipine.
BepridilThe risk or severity of adverse effects can be increased when Haloprogin is combined with Bepridil.
BuspironeThe metabolism of Buspirone can be decreased when combined with Haloprogin.
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Haloprogin.
CilnidipineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Cilnidipine.
CinnarizineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Cinnarizine.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Haloprogin.
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Haloprogin.
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Haloprogin.
DarodipineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Darodipine.
DidanosineDidanosine can cause a decrease in the absorption of Haloprogin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DiltiazemThe risk or severity of adverse effects can be increased when Haloprogin is combined with Diltiazem.
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Haloprogin.
DofetilideThe metabolism of Dofetilide can be decreased when combined with Haloprogin.
DotarizineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Dotarizine.
EfonidipineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Efonidipine.
EperisoneThe risk or severity of adverse effects can be increased when Haloprogin is combined with Eperisone.
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Haloprogin.
FelodipineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Felodipine.
FendilineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Fendiline.
FlunarizineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Flunarizine.
FosphenytoinThe serum concentration of Haloprogin can be decreased when it is combined with Fosphenytoin.
GabapentinThe risk or severity of adverse effects can be increased when Haloprogin is combined with Gabapentin.
IsradipineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Isradipine.
LacidipineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Lacidipine.
LamotrigineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Lamotrigine.
LercanidipineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Lercanidipine.
LosartanThe metabolism of Losartan can be decreased when combined with Haloprogin.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Haloprogin is combined with Magnesium Sulfate.
ManidipineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Manidipine.
MibefradilThe risk or severity of adverse effects can be increased when Haloprogin is combined with Mibefradil.
NicardipineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nicardipine.
NifedipineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nifedipine.
NiguldipineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Niguldipine.
NiludipineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Niludipine.
NilvadipineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nimesulide.
NimodipineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nimodipine.
NisoldipineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nisoldipine.
NitrendipineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nitrendipine.
PerhexilineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Perhexiline.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Haloprogin.
PimozideHaloprogin may increase the arrhythmogenic activities of Pimozide.
PinaveriumThe risk or severity of adverse effects can be increased when Haloprogin is combined with Pinaverium.
PregabalinThe risk or severity of adverse effects can be increased when Haloprogin is combined with Pregabalin.
PrenylamineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Prenylamine.
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Haloprogin.
QuinidineThe metabolism of Quinidine can be decreased when combined with Haloprogin.
RanolazineThe metabolism of Ranolazine can be decreased when combined with Haloprogin.
RisedronateThe risk or severity of adverse effects can be increased when Haloprogin is combined with Risedronate.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Haloprogin.
SucralfateSucralfate can cause a decrease in the absorption of Haloprogin resulting in a reduced serum concentration and potentially a decrease in efficacy.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Haloprogin.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Haloprogin.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Haloprogin is combined with Tolfenamic Acid.
TranilastThe risk or severity of adverse effects can be increased when Haloprogin is combined with Tranilast.
VerapamilThe risk or severity of adverse effects can be increased when Haloprogin is combined with Verapamil.
XylometazolineThe risk or severity of adverse effects can be increased when Haloprogin is combined with Xylometazoline.
ZiconotideThe risk or severity of adverse effects can be increased when Haloprogin is combined with Ziconotide.
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Haloprogin.
Food InteractionsNot Available
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23